Annual report
9987.TEDINET S100OCGE
Period2021-04-01 → 2022-03-31
Filed2022-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.23T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.13T | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥2.21T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.13T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.12T | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥13.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥9.2bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.3bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥41.5bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥36.2bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥29.0bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥22.5bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥12.6bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.9bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥28.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥30.2bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥18.8bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥14.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥8.0bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥1.14T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.19T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.17T | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥723.7bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥696.5bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥418.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥417.9bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥412.7bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥401.6bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥406.4bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥141.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥151.1bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥168.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.8bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥175.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥217.0bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥200.6bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥15.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥25.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥98.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥1.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥894m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥11.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥17.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥27.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥12.7bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.52 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥310.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥322.73 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥198.21 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,749.59 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,675.23 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,618.33 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,390.98 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,284.8 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.4% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.6% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 3.4% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.9% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 14,032 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 15,041 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 15,477 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 15,585 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 15,816 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥2.03T | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥1.93T | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥2.00T | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.92T | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.90T | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥5.3bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥2.3bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥14.9bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥11.8bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥30.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.5bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.9bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥18.6bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥8.0bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥13.8bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥6.0bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥21.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥24.7bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥14.6bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.03T | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥1.00T | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥1.00T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.08T | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.06T | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥723.8bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥701.1bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥302.5bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥303.2bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥301.0bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥296.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥305.5bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥85.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥100.4bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥156.55 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.15 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥238.38 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥263.43 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.18 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥72 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥69 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥64 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,440.25 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,398.64 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,375.27 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,244.37 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,226.22 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 29.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.8% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.6% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 103,344,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,430 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,116 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 4,244 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 4,401 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 4,474 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 75
| Segment | Item | Period | Value |
|---|---|---|---|
| The Healthcare Related Services Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥570m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥633m |
| The Healthcare Related Services Businessreportable segment | employees | at 2022-03-31 | 1510 pure |
| The Healthcare Related Services Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥181.8bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥39.0bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥142.8bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2022-03-31 | ¥63.7bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| The Insurance Pharmacy Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥703m |
| The Insurance Pharmacy Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥747m |
| The Insurance Pharmacy Businessreportable segment | employees | at 2022-03-31 | 3013 pure |
| The Insurance Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥88.8bn |
| The Insurance Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥88.8bn |
| The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥34m |
| The Insurance Pharmacy Businessreportable segment | segment assets | at 2022-03-31 | ¥38.9bn |
| The Insurance Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.3bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥13.1bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥7.3bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2022-03-31 | 8563 pure |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.14T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.09T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥51.6bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2022-03-31 | ¥980.9bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥8.4bn |
| The Pharmaceutical Manufacturing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥549m |
| The Pharmaceutical Manufacturing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥913m |
| The Pharmaceutical Manufacturing Businessreportable segment | employees | at 2022-03-31 | 946 pure |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥43.9bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥12.2bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥31.7bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment assets | at 2022-03-31 | ¥59.0bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥780m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥14.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.46T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.23T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥226.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥13.7bn |
| The Healthcare Related Services Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥185m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥531m |
| The Healthcare Related Services Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥142.6bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥35.4bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥107.2bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2021-03-31 | ¥51.6bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.2bn |
| The Insurance Pharmacy Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥372m |
| The Insurance Pharmacy Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥836m |
| The Insurance Pharmacy Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥90.1bn |
| The Insurance Pharmacy Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥90.0bn |
| The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥40m |
| The Insurance Pharmacy Businessreportable segment | segment assets | at 2021-03-31 | ¥39.0bn |
| The Insurance Pharmacy Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥1.5bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥7.1bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥7.8bn |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥2.04T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥1.99T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥50.5bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2021-03-31 | ¥956.0bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥4.1bn |
| The Pharmaceutical Manufacturing Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥505m |
| The Pharmaceutical Manufacturing Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥1.0bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥43.4bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥13.4bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥30.0bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment assets | at 2021-03-31 | ¥59.8bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥8.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥2.32T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥2.13T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥187.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥1.11T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥9.0bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2022-03-31 | 3430 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,973
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 372000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 185000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 8184000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 2092743000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 12237000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 88786000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 39006000000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 2232774000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 51591000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 31701000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 34000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 142754000000 | JPY |
| Transactions with other segments | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 226081000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 2144335000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 43938000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 88821000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 181761000000 | JPY |
| Net sales | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 2458856000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 8395000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 780000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 2284000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 2219000000 | JPY |
| Operating income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 13680000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 980896000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 58977000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 38939000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 63671000000 | JPY |
| Assets | CurrentYearInstant_TotalOfReportableSegmentsAndOthersMember | 1142485000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 7267000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 913000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 747000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 633000000 | JPY |
| Depreciation segment information | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 9562000000 | JPY |
| Investments in entities accounted for using equity method | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 8533000000 | JPY |
| Investments in entities accounted for using equity method | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | － | JPY |
| Investments in entities accounted for using equity method | CurrentYearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | － | JPY |
| Investments in entities accounted for using equity method | CurrentYearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | － | JPY |
| Investments in entities accounted for using equity method | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 8533000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 13085000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 549000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 703000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 570000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 14907000000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 165000000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | － | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 245000000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | － | JPY |
| Impairment loss el | Prior1YearDuration_UnallocatedAmountsAndEliminationMember | － | JPY |
| Impairment loss el | Prior1YearDuration | 410000000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 625000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |